Percutaneous Microwave Ablation Versus Robot-Assisted Partial Nephrectomy for Stage I Renal Cell Carcinoma: A Propensity-Matched Cohort Study Focusing Upon Long-Term Follow-Up of Oncologic Outcomes

Overview

Journal Cardiovasc Intervent Radiol

Specialty Cardiology & Vascular Diseases

Date 2024 Apr 1

PMID 38561521

Authors

David-Dimitris Chlorogiannis

Zisis Kratiras

Evgenia Efthymiou

Napoleon Moulavasilis

Nikolaos Kelekis

Michail Chrisofos

Konstandinos Stravodimos

Dimitris K Filippiadis

Affiliations

Soon will be listed here.

Abstract

Purpose: To retrospectively compare long-term oncologic outcomes of percutaneous computed tomography-guided microwave ablation (MWA) and robot-assisted partial nephrectomy (RAPN) for the treatment of stage 1 (T1a and T1b) renal cell carcinoma (RCC) patients.

Materials And Methods: Institutional database research identified all T1 RCC patients who underwent either MWA or RAPN. Models were adjusted with propensity score matching. Kaplan-Meier log-rank test analyses and Cox proportional hazard regression models were used to compare the oncologic outcomes. Patient and tumor characteristics, technical success as well as oncologic outcomes were evaluated and compared between the 2 groups.

Results: After propensity score matching, a total of 71 patients underwent percutaneous MWA (mean age 70 ± 10 years) and 71 underwent RAPN (mean age 60 ± 9 years). At 8-year follow-up, the estimated survival rates for MWA cohort were 98% (95% confidence interval [CI] 95-100%) for overall survival, 97% (95% CI 93-100%) for recurrence-free survival, and 97% (95% CI 93-100%) for metastasis-free survival. The matched cohort that underwent RAPN exhibited survival rates of 100% (95% CI 100-100%) for overall survival, 98% (95% CI 94-100%) for recurrence-free survival, and 98% (95% CI 94-100%) for metastasis-free survival. After performing log-rank testing, these rates were not significantly different (p values of 0.44, 0.67, and 0.67, respectively).

Conclusion: The results of the present study suggest that both MWA and RAPN are equally effective in terms of oncologic outcome for the treatment of T1 RCC.

Citing Articles

Image-guided percutaneous ablative treatments for renal cell carcinoma.

Auer T, Uluk Y, Grasso R, Kloeckner R, Gebauer B, Kroencke T Eur Radiol. 2025; .

PMID: 40050457 DOI: 10.1007/s00330-025-11480-w.

References

Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam J . Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur Urol. 2022; 82(5):529-542. DOI: 10.1016/j.eururo.2022.08.019. View

Du Z, Chen W, Xia Q, Shi O, Chen Q . Trends and projections of kidney cancer incidence at the global and national levels, 1990-2030: a Bayesian age-period-cohort modeling study. Biomark Res. 2020; 8:16. PMC: 7222434. DOI: 10.1186/s40364-020-00195-3. View

Lavallee L, Tanguay S, Jewett M, Wood L, Kapoor A, Rendon R . Surgical management of stage T1 renal tumours at Canadian academic centres. Can Urol Assoc J. 2015; 9(3-4):99-106. PMC: 4455632. DOI: 10.5489/cuaj.2598. View

Sun M, Bianchi M, Trinh Q, Hansen J, Abdollah F, Hanna N . Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities. BJU Int. 2012; 111(1):67-73. DOI: 10.1111/j.1464-410X.2012.11254.x. View

Campbell S, Clark P, Chang S, Karam J, Souter L, Uzzo R . Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J Urol. 2021; 206(2):199-208. DOI: 10.1097/JU.0000000000001911. View

Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A . Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017; 35(6):668-680. DOI: 10.1200/JCO.2016.69.9645. View

Kutikov A, Uzzo R . The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009; 182(3):844-53. DOI: 10.1016/j.juro.2009.05.035. View

Puijk R, Ahmed M, Adam A, Arai Y, Arellano R, De Baere T . Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative. Radiology. 2021; 301(3):533-540. DOI: 10.1148/radiol.2021203715. View

Filippiadis D, Binkert C, Pellerin O, Hoffmann R, Krajina A, Pereira P . Cirse Quality Assurance Document and Standards for Classification of Complications: The Cirse Classification System. Cardiovasc Intervent Radiol. 2017; 40(8):1141-1146. DOI: 10.1007/s00270-017-1703-4. View

10.

Clavien P, Barkun J, De Oliveira M, Vauthey J, Dindo D, Schulick R . The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009; 250(2):187-96. DOI: 10.1097/SLA.0b013e3181b13ca2. View

11.

Yao X, Wang X, Speicher P, Hwang E, Cheng P, Harpole D . Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017; 109(8). PMC: 6059208. DOI: 10.1093/jnci/djw323. View

12.

Zhao Q, Luo J, Su Y, Zhang Y, Tu G, Luo Z . Propensity score matching with R: conventional methods and new features. Ann Transl Med. 2021; 9(9):812. PMC: 8246231. DOI: 10.21037/atm-20-3998. View

13.

Weight C, Lieser G, Larson B, Gao T, Lane B, Campbell S . Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. Eur Urol. 2010; 58(2):293-8. DOI: 10.1016/j.eururo.2010.04.033. View

14.

Weight C, Larson B, Gao T, Campbell S, Lane B, Kaouk J . Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology. 2010; 76(3):631-7. DOI: 10.1016/j.urology.2009.11.087. View

15.

Ma R, Yan Z, Hamdy N, Zhan X, Li Z . Editorial: Advances in approaches for function-preserving gastric cancer surgery. Front Surg. 2024; 10:1335914. PMC: 10853458. DOI: 10.3389/fsurg.2023.1335914. View

16.

Morkos J, Porosnicu Rodriguez K, Zhou A, Kolarich A, Frangakis C, Rodriguez R . Percutaneous Cryoablation for Stage 1 Renal Cell Carcinoma: Outcomes from a 10-year Prospective Study and Comparison with Matched Cohorts from the National Cancer Database. Radiology. 2020; 296(2):452-459. DOI: 10.1148/radiol.2020192325. View

17.

Efthymiou E, Siatelis A, Liakouras C, Makris G, Chrisofos M, Kelekis A . Computed Tomography-Guided Percutaneous Microwave Ablation for Renal Cell Carcinoma: Impact of Tumor Size on the Progression Survival Rates. Diagnostics (Basel). 2021; 11(9). PMC: 8472140. DOI: 10.3390/diagnostics11091618. View

18.

Lucignani G, Rizzo M, Ierardi A, Piasentin A, De Lorenzis E, Trombetta C . Percutaneous Microwave Ablation is Comparable to Cryoablation for the Treatment of T1a Renal Masses: Results From a Cross-Sectional Study. Clin Genitourin Cancer. 2022; 20(6):e506-e511. DOI: 10.1016/j.clgc.2022.07.004. View

19.

Castellana R, Natrella M, Fanelli G, Lancellotta V, Cornacchione P, Castellana M . Efficacy and safety of MWA versus RFA and CA for renal tumors: A systematic review and meta-analysis of comparison studies. Eur J Radiol. 2023; 165:110943. DOI: 10.1016/j.ejrad.2023.110943. View

20.

Efthymiou E, Velonakis G, Charalampopoulos G, Mazioti A, Brountzos E, Kelekis N . Computed tomography-guided percutaneous microwave ablation for renal cell carcinoma: evaluating the performance of nephrometry scores. Eur Radiol. 2023; 33(11):7388-7397. DOI: 10.1007/s00330-023-09774-y. View